AI-assisted protocol design helps sponsors test feasibility before a trial begins, by modeling how eligibility criteria affect the patient pool, estimating site and participant burden and comparing designs against historical studies. Its greatest value is catching operational problems while they are still cheap to fix.
Protocol amendments are one of the most expensive and avoidable problems in clinical development. Research from the Tufts Center for the Study of Drug Development has shown that a large proportion of protocols require substantial amendments, many of which could have been prevented with better upfront design. Each amendment triggers regulatory submissions, site retraining, contract changes and delays.
How can AI improve protocol design?
Several applications have practical value today.
Eligibility modeling. By running inclusion and exclusion criteria against real-world data, AI can show how many patients would qualify and which individual criteria eliminate the most people. Sometimes a single lab threshold halves the eligible population without a strong scientific reason.
Complexity benchmarking. Models can compare the number of procedures, visits and endpoints against similar historical protocols and flag designs that are unusually burdensome.
Participant burden assessment. AI can estimate time commitment, travel and invasive procedures per participant, which helps predict retention risk.
Document drafting and consistency checks. Generative AI can draft protocol sections and check for internal inconsistencies, such as a schedule of assessments that does not match the procedures described in the text.
Where human expertise remains essential
AI can tell you a protocol is complex. It cannot tell you which complexity is scientifically necessary. That judgment belongs to clinical scientists, statisticians, regulatory experts and, increasingly, patients and site staff who review the design before finalization.
I encourage sponsors to treat AI outputs as input to a structured protocol review, not a verdict. The most useful conversation often starts with the model's flag: "This exclusion criterion removes 40 percent of eligible patients. Do we need it?" Sometimes the answer is yes. Often, on reflection, it is no.
Operational input early
One of the most persistent gaps I have observed is the absence of operational voices during protocol development. Clinical operations teams, CRO partners and site representatives see feasibility problems that scientific teams do not. AI tools can make that feedback more concrete and harder to dismiss.
For emerging biotechs working with limited staff, combining AI-based feasibility modeling with an experienced operational review before protocol finalization is one of the highest-return investments available.
A protocol is a promise to regulators, sites and patients. AI helps make sure it is one you can keep.
